Literature DB >> 22815381

Incidence of genital warts in Sweden before and after quadrivalent human papillomavirus vaccine availability.

Amy Leval1, Eva Herweijer, Lisen Arnheim-Dahlström, Hasse Walum, Emma Frans, Pär Sparén, Julia F Simard.   

Abstract

BACKGROUND: More than 90% of genital warts (GW) cases are caused by human papillomavirus (HPV) types 6 and 11. The introduction of HPV vaccines necessitates the estimation of the population-based incidence of GW immediately before and after vaccination uptake.
METHODS: Incidence proportions were calculated using the entire population aged 10–44 years living in Sweden during 2006–2010. The Prescribed Drug Register and the National Patient Register were used to define GW episodes. Time trends were estimated using Poisson regression.
RESULTS: In 2010, age-stratified incidence proportions of GW were highest for 20-year-old women (956 cases/100 000), while the incidence proportion among males was greatest at the slightly older age of 24 years (1137 cases/100 000). Crude rates were marginally higher among males than among females during 2006–2007 and appeared to later diverge. Between 2008 and 2010, the overall incidence appeared to increase among males, and the incidence among females declined. Females aged 17 and 18 years had a >25% decline in GW rates between 2006 and 2010, with significant decreases through the age of 25 years.
CONCLUSIONS: This study provides a reasonable estimation of the incidence of GW in the Swedish population by use of register data, with results comparable to those from previous smaller studies. There was a downward trend of GW incidence among younger females between 2006 and 2010.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22815381     DOI: 10.1093/infdis/jis405

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  27 in total

1.  Trends in the Prevalence of Anogenital Warts Among Patients at Sexually Transmitted Disease Clinics-Sexually Transmitted Disease Surveillance Network, United States, 2010-2016.

Authors:  Laura M Mann; Eloisa Llata; Elaine W Flagg; Jaeyoung Hong; Lenore Asbel; Juli Carlos-Henderson; Roxanne P Kerani; Robert Kohn; Preeti Pathela; Christina Schumacher; Elizabeth A Torrone
Journal:  J Infect Dis       Date:  2019-04-16       Impact factor: 5.226

2.  Prevalence of genital warts among sexually transmitted disease clinic patients-sexually transmitted disease surveillance network, United States, January 2010 to December 2011.

Authors:  Eloisa Llata; Mark Stenger; Kyle Bernstein; Sarah Guerry; Roxanne Kerani; River Pugsley; Preeti Pathela; Irina Tabidze; Hillard Weinstock
Journal:  Sex Transm Dis       Date:  2014-02       Impact factor: 2.830

3.  Impact of Number of Human Papillomavirus Vaccine Doses on Genital Warts Diagnoses Among a National Cohort of U.S. Adolescents.

Authors:  Rebecca B Perkins; Mengyun Lin; Sherrie F Wallington; Amresh Hanchate
Journal:  Sex Transm Dis       Date:  2017-06       Impact factor: 2.830

4.  Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Norma Pérez; Marc Brisson
Journal:  Lancet       Date:  2019-06-26       Impact factor: 79.321

5.  Evaluation of safety and immunogenicity of a quadrivalent human papillomavirus vaccine in healthy females between 9 and 26 years of age in Sub-Saharan Africa.

Authors:  Nelly Mugo; Nana Akosua Ansah; Deborah Marino; Alfred Saah; Elizabeth I O Garner
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Prevalence of anogenital warts among participants in private health plans in the United States, 2003-2010: potential impact of human papillomavirus vaccination.

Authors:  Elaine W Flagg; Robert Schwartz; Hillard Weinstock
Journal:  Am J Public Health       Date:  2013-06-13       Impact factor: 9.308

Review 7.  Population impact of HPV vaccines: summary of early evidence.

Authors:  Susan Hariri; Lauri E Markowitz; Eileen F Dunne; Elizabeth R Unger
Journal:  J Adolesc Health       Date:  2013-12       Impact factor: 5.012

Review 8.  Impact of HPV vaccination on anogenital warts and respiratory papillomatosis.

Authors:  Zoon Wangu; Katherine K Hsu
Journal:  Hum Vaccin Immunother       Date:  2016-05-23       Impact factor: 3.452

Review 9.  Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis.

Authors:  Mélanie Drolet; Élodie Bénard; Marie-Claude Boily; Hammad Ali; Louise Baandrup; Heidi Bauer; Simon Beddows; Jacques Brisson; Julia M L Brotherton; Teresa Cummings; Basil Donovan; Christopher K Fairley; Elaine W Flagg; Anne M Johnson; Jessica A Kahn; Kimberley Kavanagh; Susanne K Kjaer; Erich V Kliewer; Philippe Lemieux-Mellouki; Lauri Markowitz; Aminata Mboup; David Mesher; Linda Niccolai; Jeannie Oliphant; Kevin G Pollock; Kate Soldan; Pam Sonnenberg; Sepehr N Tabrizi; Clare Tanton; Marc Brisson
Journal:  Lancet Infect Dis       Date:  2015-03-03       Impact factor: 25.071

10.  Quadrivalent human papillomavirus vaccine effectiveness: a Swedish national cohort study.

Authors:  Amy Leval; Eva Herweijer; Alexander Ploner; Sandra Eloranta; Julia Fridman Simard; Joakim Dillner; Cecilia Young; Eva Netterlid; Pär Sparén; Lisen Arnheim-Dahlström
Journal:  J Natl Cancer Inst       Date:  2013-03-13       Impact factor: 13.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.